NCT04382898: A reported trial by Biontech SE
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04382898 |
|---|---|
| Title | First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 19, 2019 |
| Completion date | Jan. 23, 2024 |
| Required reporting date | Jan. 22, 2025, midnight |
| Actual reporting date | Jan. 17, 2025 |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | None |